# US 2024/0199635 A1 · Tetrahydrothieno pyridine derivatives as ddrs inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199635 A1
- Document ID: US20240199635A1
- Status: Published application
- Kind: A1
- Application number: 18/283,867
- Filed: 2022-03-25
- Published: 2024-06-20
- Earliest claimed: 2021-03-26
- Assignees: Chiesi Farmaceutici S.p.A.
- Applicants: Chiesi Farmaceutici S.P.A.
- Inventors: Laura CARZANIGA; Fabio RANCATI; Andrea RIZZi; Keith Christopher KNIGHT; Anna KARAWAJCZYK; Barbara Karolina WOLEK; Toby Matthew Grover MULLINS; Ben Paul WHITTAKER
- Web page: https://patentgrep.com/patent/US20240199635A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.

## Claims

### Claim at position 1

1: A compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein:
L is selected from the group consisting of —C(O)— and —CH2—;
Hy is a monocyclic heteroaryl optionally substituted with one or more groups selected from —(C1-C4)alkyl, a halogen atom, cyano, —(CH2)nNR4R5, —NH-heterocycloalkyl, —O—(C1-C6)alkyl, —(C1-C6)haloalkyl, —C(O)NH—(C1-C6)alkylene-NR4R5, —O—(C1-C6)alkylene-cycloalkyl, —NHC(O)—(C1-C6)alkyl, —NHC(O)—(C1-C6)alkylene-NR4R5, —NHC(O)—(C1-C6)alkylene-O—(C1-C4)alkyl, —NH—(C1-C6)alkylene-O—(C1-C4)alkyl, —NH—(C1-C6)alkylene-OH, -heteroaryl optionally substituted by one or more of —(C1-C4)alkyl and —NH-heteroaryl, wherein the heteroaryl is optionally substituted by one or more —(C1-C4)alkyl, and heterocycloalkyl optionally substituted by one or more groups selected from oxo and —(C1-C6)alkyl;
R1 is selected from the group consisting of:
Het which is an heteroaryl optionally substituted with one or more groups selected from —(C1-C4)alkyl, —(C1-C4)haloalkyl and aryl, wherein the aryl is optionally substituted with one or more groups selected from —(C1-C4)alkyl and a halogen atom; and
X
wherein:
R2 is selected from the group consisting of —O(C1-C4)haloalkyl, a halogen atom, —O(C3-C7)cycloalkyl, and —(C1-C4)haloalkyl; and
R3 is H or is selected from the group consisting of a halogen atom, cyano, —O(C1-C4)alkyl, —O(C1-C4)haloalkyl, heterocycloalkyl-(C1-C4)alkylene-, —(C1-C4)alkylene-heterocycloalkyl-NR4R5, and heteroaryl optionally substituted with one or more —(C1-C4)alkyl, and wherein the heterocycloalkyl is optionally substituted with one or more —(C1-C4)alkyl;
n is 0, 1 or 2;
R4 is H or —(C1-C4)alkyl; and
R5 is H or —(C1-C4)alkyl.

### Claim at position 2 (depends on 1)

2: The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound is represented by formula (Ia):

### Claim at position 3 (depends on 2)

3: The compound or pharmaceutically acceptable salt thereof according to claim 2, wherein the compound is represented by formula (Iaa);

### Claim at position 4 (depends on 1)

4: The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is selected from the group consisting of:
N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-6-(pyridin-3-ylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-6-(pyrimidin-5-ylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-6-(pyrimidin-5-ylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-fluoro-5-(trifluoromethyl)phenyl)-6-(pyrimidin-5-ylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-(pyrimidin-5-ylmethyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-fluoro-5-(trifluoromethoxy)phenyl)-6-(pyrimidin-5-ylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-(1,1-difluoroethyl)phenyl)-6-(pyrimidin-5-ylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-(difluoromethoxy)-5-fluorophenyl)-6-(pyrimidin-5-ylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-(difluoromethoxy)phenyl)-6-(pyrimidin-5-ylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-cyano-5-(trifluoromethyl)phenyl)-6-(pyrimidin-5-ylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((4-(2-methoxyacetamido)pyridin-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((5-cyanopyridin-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((5-chloropyridin-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((5-methoxypyridin-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((5-methylpyridin-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-(trifluoromethyl)phenyl)-6-((5-(trifluoromethyl)pyridin-3-yl)methyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((5-fluoropyridin-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-(pyridin-3-ylmethyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((3-aminopyrazin-2-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((2-aminopyrimidin-5-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((5-(4-methyl-3-oxopiperazin-1-yl)pyridin-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((5-(1,1-dioxidothiomorpholino)pyridin-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((5-(2-(dimethylamino)acetamido)pyridin-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-fluoro-5-(trifluoromethyl)phenyl)-6-((2-(oxetan-3-ylamino)pyrimidin-5-yl)methyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((2-aminopyrimidin-5-yl)methyl)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((2-acetamidopyrimidin-5-yl)methyl)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-fluoro-5-(trifluoromethyl)phenyl)-6-((2-(methylamino)pyrimidin-5-yl)methyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-fluoro-5-(trifluoromethyl)phenyl)-6-((2-((2-methoxyethyl)amino)pyrimidin-5-yl)methyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((6-acetamidopyridin-3-yl)methyl)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((2-aminopyridin-3-yl)methyl)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-fluoro-5-(trifluoromethyl)phenyl)-6-((2-((2-hydroxyethyl)amino)pyrimidin-5-yl)methyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((4-aminopyrimidin-5-yl)methyl)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((3-aminopyrazin-2-yl)methyl)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((2-amino-4-methylpyrimidin-5-yl)methyl)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
N-(3-fluoro-5-(trifluoromethyl)phenyl)-6-((6-(methylamino)pyridin-3-yl)methyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
(R)-6-((2-aminopyrimidin-5-yl)methyl)-N-(3-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
(R)—N-(3-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-6-((4-(2-fluoropropan-2-yl)pyrimidin-5-yl)methyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
(R)—N-(3-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-6-((4-methoxypyrimidin-5-yl)methyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
(R)-6-((4-cyclopropoxypyrimidin-5-yl)methyl)-N-(3-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
(R)—N-(3-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-6-((5-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((2-aminopyrimidin-5-yl)methyl)-N-(3-((dimethylamino)methyl)-5-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide;
6-((2-aminopyrimidin-5-yl)methyl)-N-(3-(1,1-difluoroethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide; and
6-((2-aminopyrimidin-5-yl)methyl)-N-(3-cyano-5-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide.

### Claim at position 5 (depends on 1)

5: The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound is
represented by formula (Iaa′):

### Claim at position 6 (depends on 1)

6: The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound is
represented by formula (Iaa″)

### Claim at position 7 (depends on 2)

7: The compound or pharmaceutically acceptable salt thereof according to claim 2, wherein the compound is represented by formula (Iab):

### Claim at position 8 (depends on 1)

8: The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is represented by formula (Ib);

### Claim at position 9 (depends on 8)

9: The compound or pharmaceutically acceptable salt thereof according to claim 8, wherein the compound is represented by formula (Iba):

### Claim at position 10 (depends on 1)

10: A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 1, in admixture with one or more pharmaceutically acceptable carriers or excipients.

### Claim at position 11 (depends on 10)

11: The pharmaceutical composition according to claim 10 formulated for administration by inhalation.

### Claim 12

(canceled)

### Claim at position 13 (depends on 1)

13: A method for treating a disease, disorder, or condition associated with dysregulation of Discoidin Domain Receptor, comprising administering the compound or pharmaceutically acceptable salt thereof according to claim 1 to subject in need of such treatment.

### Claim at position 14 (depends on 1)

14: A method for treating at least one selected from fibrosis and a disease, disorder, or condition involving fibrosis comprising administering the compound or pharmaceutically acceptable salt thereof according to claim 1 to a subject in need of such treatment.

### Claim at position 15 (depends on 1)

15: A method for treating at least one selected from pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), hepatic fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis, and systemic sclerosis, comprising administering the compound or pharmaceutically acceptable salt thereof according to claim 1 to a subject in need of such treatment.

### Claim at position 16 (depends on 1)

16: A method for treating idiopathic pulmonary fibrosis (IPF), comprising administering the compound or pharmaceutically acceptable salt thereof according to claim 1 to a subject in need of such treatment.
